Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by AYLWARD, M.
Right arrow Articles by MADDOCK, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by AYLWARD, M.
Right arrow Articles by MADDOCK, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1974 British Society for Rheumatology

review-article

PLASMA L-TRYPTOPHAN CONCENTRATIONS IN CHRONIC RHEUMATIC DISEASES AND THE EFFECTS OF SOME ANTIRHEUMATIC DRUGS ON THE BINDING OF THE AMINO-ACID TO PLASMA PROTEINS IN VIVO AND IN VITRO*

MANSEL AYLWARD and JEFFREY MADDOCK

From the Research Division, Merthyr General Hospital, Merthyr Tydfil, Glamorgan, and the Department of Pathology, Singleton Hospital Swansea, Glamorgan

L-TRYPTOPHAN may be used as a model endogenous molecule to study the binding characteristics of the plasma proteins of patients with connective-tissue diseases. A drug's ability to displace L-tryptophan from binding to human serum albumin may also represent a new in-vitro assay for screening drugs for potential anti-inflammatory activity. In patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, antirheumatic drugs displace L-tryptophan from plasma proteins in vivo, whereas withdrawal of such therapy is associated with excessive binding of the amino-acid to plasma proteins. In children with Still's disease, virtually all plasma tryptophan exists in the protein-bound form, and protein-bound tryptophan is less easily displaced from Still's disease plasma than from healthy children's plasma by antirheumatic drugs in vitro. Results obtained with the novel in-vitro assay described indicate its greater sensitivity than the Mizushima test for screening antirheumatic agents.

*Based on a paper presented at a combined meeting of the British Association for Rheumatology and Rehabilitation with the Royal Society of Medicine, Section of Rheumatology and Rehabilitation, Cardiff, September 1973.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.